Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of SRT501 With or Without Bortezomib in Multiple Myeloma
2008-005112-41Phase 2Terminated
- Sponsor
- Sirtris Pharmaceuticals
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SRT501 in multiple myeloma (MM) (2 arms), sponsored by Sirtris Pharmaceuticals. Primary endpoint: Safety and tolerability of SRT501 with or without bortezomib. Started Oct 2008; status: terminated.
02
Drugs
SRT501
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-005112-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005112-41.